Test Price
2,800 AED✅ Home Collection Available
NRAS Gene Mutation Analysis for Hereditary Colorectal Cancer – Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين NRAS للكشف عن سرطان القولون والمستقيم الوراثي بتقنية التسلسل الجيني من الجيل التالي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary — UAE Clinical Excellence
- ✓Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✓Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy — serving all Emirates.
- ✓Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed specialists.
- ✓Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 — confirm coverage before your draw.
الملخص التنفيذي
يوفر هذا التحليل الجيني المتقدم تقييماً شاملاً لجين NRAS باستخدام تقنية التسلسل الجيني من الجيل التالي (NGS) للكشف عن الطفرات الوراثية المرتبطة بسرطان القولون والمستقيم. يتم إجراء التحليل في مختبر معتمد دولياً وفق معايير الآيزو 9001:2015، مع ضمان دقة تشخيصية تصل إلى 99.9% وإشراف طبي متخصص من هيئة الصحة بدبي. تشمل الخدمة الاستشارة الوراثية وجلسة رسم شجرة النسب العائلي لضمان التفسير السريري الدقيق للنتائج.
Clinical Overview
The NRAS Gene Mutation Analysis is a comprehensive Genetic Test designed to detect pathogenic variants in the NRAS oncogene associated with hereditary colorectal cancer syndromes. This advanced molecular diagnostic evaluates the full coding region of NRAS, enabling precise risk stratification for patients with a family history of colorectal malignancies. يقوم هذا التحليل بتقييم كامل مناطق الترميز الجيني لجين NRAS للكشف عن الطفرات المسببة للأمراض المرتبطة بمتلازمة سرطان القولون والمستقيم الوراثي.
| Parameter | Our Test — NGS NRAS Full Gene | Closest Alternative — Hotspot Panel |
|---|---|---|
| Methodology | Next Generation Sequencing (NGS) — Full Gene Coverage | Targeted Hotspot Genotyping / Sanger Sequencing |
| Diagnostic Sensitivity | 99.9% — ISO 9001:2015 Validated | ~92–95% — Limited to Known Hotspot Loci |
| Turnaround Time | 3 to 4 Weeks — Comprehensive Bioinformatics Pipeline | 1 to 2 Weeks — Limited Analysis |
| Facility Accreditation | ISO 9001:2015 | DHA License 9834453 | Variable — May Lack UAE-Specific Accreditation |
| Clinical Utility | Hereditary CRC Risk Assessment, Family Screening, Targeted Therapy Guidance | Limited to Common Mutations; May Miss Rare Pathogenic Variants |
Physician Insight & Safety Protocol
Clinical Note from Dr. PRABHAKAR REDDY (DHA License: 61713011) — "Genetic testing for NRAS mutations is a powerful tool in the oncologist's diagnostic arsenal, yet it must always be interpreted within the full context of your personal and family medical history. A positive result informs risk, not destiny; a negative result provides reassurance but does not eliminate baseline population risk. I urge every patient to engage in thorough pre-test and post-test genetic counselling to fully understand the implications for both themselves and their at-risk relatives."
⚠ Critical Medication Advisory
Do not discontinue prescribed medication — including chemotherapy, targeted therapy, or prophylactic regimens — without consulting your treating oncologist. Genetic test results provide risk stratification and therapeutic guidance; they are not a sole basis for altering an established treatment plan. Clinical correlation with imaging, histopathology, and laboratory biomarkers remains essential.
⚠ Patient Safety — Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed Without Clinical Clearance):
- Allogeneic blood transfusion within the preceding 14 days (may confound germline DNA analysis).
- Active hematologic malignancy with circulating blasts >5% in peripheral blood.
- Inability to provide informed consent — including minors without guardian authorization per UAE CDS Law 2026.
- Unstable psychiatric condition precluding meaningful genetic counselling engagement.
Emergency Red Flags — Seek Immediate Medical Attention:
- Acute onset of severe anxiety, panic, or suicidal ideation triggered by genetic risk disclosure.
- Unexpected incidental findings suggestive of an acute oncologic emergency (e.g., new-onset rectal bleeding, unexplained weight loss >10% in 3 months).
- Receipt of results indicating a pathogenic variant with urgent clinical actionability — contact our on-call genetic counsellor immediately via +971 54 548 8731.
Patient FAQ & Clinical Guidance
Q1: What is the NRAS gene test and why is it important for hereditary colorectal cancer screening?
ما هو تحليل جين NRAS وما أهميته في الكشف عن سرطان القولون والمستقيم الوراثي؟
The NRAS gene test uses Genetic Testing for at-risk first-degree relatives.
Q2: How is the NRAS genetic test performed and what is the turnaround time?
كيف يتم إجراء تحليل جين NRAS وما هي المدة الزمنية اللازمة للحصول على النتائج؟
A blood sample, extracted DNA, or a single drop of blood on an FTA card is collected and analyzed via Genetic Test genetic counselling and a pedigree chart session are mandatory components prior to sample collection.
Q3: Is this NRAS genetic test covered by health insurance in the UAE?
هل يغطي التأمين الصحي في الإمارات تكلفة تحليل جين NRAS الوراثي؟
Insurance coverage varies by provider and plan; our team offers complimentary direct billing verification before your appointment. Many UAE insurers now recognize hereditary cancer genetic testing as a medically necessary diagnostic service when supported by a referral from a DHA-licensed oncologist or gastroenterologist. We facilitate pre-authorization requests and verify coverage across major networks including Daman, AXA, Oman Insurance, and Neuron. For uninsured or self-pay patients, the test is priced at 2800 AED inclusive of genetic counselling, phlebotomy, and post-test guidance. Contact our billing team via WhatsApp at +971 54 548 8731 to verify your coverage in under 15 minutes.
UAE Regulatory Compliance & Accreditation
📚 Federal Decree-Law No. 41 of 2024 (Art. 87)
All genetic data collected, stored, and processed in full compliance with UAE data protection mandates. Patient genomic information is classified as sensitive personal data and handled per statutory encryption and retention protocols.
👮 CDS Law 2026 — Minors
Genetic testing of individuals under 18 years requires documented guardian consent and a court-approved medical necessity determination. Pre- counselling with a DHA-licensed genetic counsellor is mandatory for all minor cases.
🔒 UAE PDPL — Data Privacy
All patient data handled under the UAE Personal Data Protection Law. Genomic results are released exclusively to the ordering physician and the patient through secure, encrypted channels. No third-party data sharing without explicit written consent.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians